ReviewBritish journal of cancer2022
Toward platelet transcriptomics in cancer diagnosis, prognosis and therapy.
Review in British journal of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 24 citations in OpenAlex.
- A novel metacyte metafer classifier for platelet morphology using long COVID as a model.Journal of thrombosis and thrombolysis · 2026Article
- A Multi-Omics and machine learning platelet-related prognostic signature in multiple myeloma.Annals of hematology · 2026Article
- Unsupervised and supervised machine learning to identify variability of tumor-educated platelets and association with pan-cancer: A cross-national study.Fundamental research · 2026Article
- Stratified assessment of platelets in sepsis: from dynamic counts to functional phenotypes.Frontiers in immunology · 2026Review
- Tumor-mediated remote regulation of peripheral blood platelets.Cell biology and toxicology · 2025Review
- A predictive model using platelets and neutrophil-to-lymphocyte ratio for the number of lymph node metastases in papillary thyroid carcinoma: a retrospective analysis.Gland surgery · 2025Article
- Causal relationships between gut microbiota and urothelial carcinoma mediated by inflammatory cytokines and blood cell traits identified through Mendelian randomization analysis.Discover oncology · 2025Article
- Identification of Progression-Associated Biomarkers in Lung Cancer Based on the Integrated Analysis of RNA Sequencing Data From Platelets and Tumor Tissues.International journal of genomics · 2025Article
- Prospective, international, multisite comparison of platelet isolation techniques for genome-wide transcriptomics: communication from the SSC of the ISTH.Journal of thrombosis and haemostasis : JTH · 2024Article
- [Prognostic analysis of childhood T-lymphoblastic lymphoma treated with leukemia regimen].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2024Article
- Plasma-Free Blood as a Potential Alternative to Whole Blood for Transcriptomic Analysis.Phenomics (Cham, Switzerland) · 2024Article
- Article
- Heterogeneity of platelets and their responses.Research and practice in thrombosis and haemostasis · 2024Article
- Platelet proteo-transcriptomic profiling validates mediators of thrombosis and proteostasis in patients with myeloproliferative neoplasms.bioRxiv : the preprint server for biology · 2023Article
- Emerging Role of Tumor-Educated Platelets as a New Liquid Biopsy Tool for Colorectal Cancer.Archives of Iranian medicine · 2023Review
- Revealing platelet-related subtypes and prognostic signature in pancreatic adenocarcinoma.BMC medical genomics · 2023Article
- Blood platelets as an RNA biomarker platform for neuro-oncological diseases.Neuro-oncology advances · 2022Article
- Aspirin for the Primary Prevention of Cardiovascular Disease: Time for a Platelet-Guided Approach.Arteriosclerosis, thrombosis, and vascular biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Widespread adoption of next-generation techniques such as RNA-sequencing (RNA-seq) has enabled research examining the transcriptome of anucleate blood platelets in health and disease, thus revealing a rich platelet transcriptomic signature that is reprogrammed in response to disease. Platelet signatures not only capture information from parent megakaryocytes and progenitor hematopoietic stem cells but also the bone marrow microenvironment, and underlying disease states. In cancer, the substantive body of research in patients with solid tumours has identified distinct signatures in 'tumour-educated platelets', reflecting influences of the tumour, stroma and vasculature on splicing, sequestration of tumour-derived RNAs, and potentially cytokine and microvesicle influences on megakaryocytes. More recently, platelet RNA expression has emerged as a highly sensitive approach to profiling chronic progressive haematologic malignancies, where the combination of large data cohorts and machine-learning algorithms enables precise feature selection and potential prognostication. Despite these advances, however, our ability to translate platelet transcriptomics toward clinical diagnostic and prognostic efforts remains limited. In this Perspective, we present a few actionable steps for our basic, translational and clinical research communities in advancing the utility of the platelet transcriptome as a highly sensitive biomarker in cancer and collectively enable efforts toward clinical translation and patient benefit.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.